Intellia Therapeutics (NTLA) Change in Acquisitions & Divestments (2019 - 2026)

Intellia Therapeutics (NTLA) has 8 years of Change in Acquisitions & Divestments data on file, last reported at $113.4 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 36.42% year-over-year to $113.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $486.8 million (down 50.19% YoY) and the FY2025 annual result came in at $551.7 million, down 48.29% from the prior year.
• Change in Acquisitions & Divestments improved to $113.4 million in Q1 2026 per NTLA's latest filing, from $94.7 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $321.6 million in Q4 2024 and bottomed at $93.7 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $199.7 million (2024), against an average of $192.2 million.
• The widest annual swing landed in 2023, when Change in Acquisitions & Divestments soared 181.24%; it then tumbled 70.55% in 2025.
• Tracing NTLA's Change in Acquisitions & Divestments over 5 years: stood at $210.2 million in 2022, then fell by 6.17% to $197.2 million in 2023, then jumped by 63.08% to $321.6 million in 2024, then plunged by 70.55% to $94.7 million in 2025, then advanced by 19.69% to $113.4 million in 2026.
• Per Business Quant, the three latest NTLA Change in Acquisitions & Divestments figures stand at $113.4 million (Q1 2026), $94.7 million (Q4 2025), and $115.9 million (Q3 2025).

Peer Comparison